Intelligence · Clinical Development
Pipeline search results
Programs matching “Astra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 467 pipeline programs matching "Astra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
D910GC00001
AstraZeneca AB
Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).
1 trial -
D910PC00001 - Volga
AstraZeneca AB
Bladder Cancer
1 trial -
D910SC00001/KUNLUN
AstraZeneca AB
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
1 trial -
D910VC00001
AstraZeneca AB
Locoregional Hepatocellular Carcinoma (HCC)
1 trial -
D9180C00003
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
D9180C00004
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
D9180C00012
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
D9180C00015
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
D9268C00001
AstraZeneca AB
"Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"
1 trial -
D926PC00001
AstraZeneca AB
Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
1 trial -
D926QC00001
AstraZeneca AB
Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
1 trial -
D926TC00001
AstraZeneca AB
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature
1 trial -
D9311C00001
AstraZeneca AB
Endometrial Cancer
1 trial -
D933AC00001
AstraZeneca AB
First-line patients with advanced biliary tract cancers (BTC)
1 trial -
D933QC00001
AstraZeneca AB
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
1 trial -
D933SC00001
AstraZeneca AB
Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
1 trial -
D9481C00001
AstraZeneca AB
Hyperkalaemia
1 trial -
D9604C00001
AstraZeneca AB
Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.
1 trial -
D9612C09998
AstraZeneca AB
Erosive Esophagitis
1 trial -
D9670C00001
AstraZeneca AB
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.
1 trial -
D967RC00001
AstraZeneca AB
Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)
1 trial -
D967SC00001
AstraZeneca AB
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
1 trial -
D967UC00001
AstraZeneca AB
HER2-positive metastatic breast cancer
1 trial -
D9722C00001
AstraZeneca AB
Advanced Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.